Abstract
Programmed death receptor 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) are immune checkpoint inhibitors that are effectively esteemed destinations of immunotherapies for the management of melanoma and several cancers. The monotherapy included monoclonal antibodies approved such as Ipilimumab, Pembrolizumab, and Nivolumab planned to restrict with T-cell inhibitory signals to activate the immune responses to cancers. Combined treatment of immune checkpoint blockers can promote results compared to monotherapy in specific patient groups and these clinical advantages can be reported from particular immune mechanisms of action. Although, treatment with checkpoint blockers combinations are present important clinical challenges and raised rates of immune related adverse incidents.
 Keywords: Cancer, Checkpoint Inhibitors, T-cell, Immunotherapy, Biomarker
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
